Oncotelic Therapeutics, Inc. APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition
Oncotelic Therapeutics, Inc. (OTLC) reported APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition of $902.14 thousand for the 12-month period ending 2022-12-31, per its 10-K filed 2024-04-12.
Discontinued › Shareholders' Equity › Adjustments to Additional Paid in Capital › APIC, Share-Based Payment Arrangement, Increase for Cost Recognition
us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition · last filed 2024-04-12
- Oncotelic Therapeutics, Inc. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2022-09-30 was $303.69K, a 1.27% increase year-over-year.
- Oncotelic Therapeutics, Inc. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2022-06-30 was $25.20K.
- Oncotelic Therapeutics, Inc. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2022-03-31 was $297.36K.
- Oncotelic Therapeutics, Inc. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2021-09-30 was $299.89K.
- Oncotelic Therapeutics, Inc. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2022 was $902.14K, a 18.19% increase from fiscal 2021.
- Oncotelic Therapeutics, Inc. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2021 was $763.31K, a 64.46% decline from fiscal 2020.
- Oncotelic Therapeutics, Inc. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2020 was $2.15M.
| Period end | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2022-12-31 | $902.14K 10-K · filed 2024-04-12 | |||
| 2022-09-30 | $303.69K 10-Q · filed 2023-11-14 | $328.88K derived: sum of 2 quarters · filed 2023-11-14 | $626.24K derived: sum of 3 quarters · filed 2023-11-14 | |
| 2022-06-30 | $25.20K 10-Q · filed 2023-11-14 | $322.56K derived: sum of 2 quarters · filed 2023-11-14 | ||
| 2022-03-31 | $297.36K 10-Q · filed 2023-11-14 | |||
| 2021-12-31 | $763.31K 10-K/A · filed 2023-04-20 | |||
| 2021-09-30 | $299.89K 10-Q · filed 2022-11-18 | |||
| 2020-12-31 | $2.15M 10-K · filed 2022-04-15 | |||
| 2020-03-31 | $2.15M 10-Q · filed 2021-11-22 |